These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

731 related items for PubMed ID: 27916347

  • 1. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
    Horiuchi T, Uwagawa T, Shirai Y, Saito N, Iwase R, Haruki K, Shiba H, Ohashi T, Yanaga K.
    J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
    [Abstract] [Full Text] [Related]

  • 2. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
    Waters JA, Matos J, Yip-Schneider M, Aguilar-Saavedra JR, Crean CD, Beane JD, Dumas RP, Suvannasankha A, Schmidt CM.
    Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for pancreatic cancer in mice.
    Fujiwara Y, Shiba H, Iwase R, Haruki K, Furukawa K, Uwagawa T, Misawa T, Ohashi T, Yanaga K.
    J Am Coll Surg; 2013 Feb; 216(2):320-32.e3. PubMed ID: 23219147
    [Abstract] [Full Text] [Related]

  • 4. Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation.
    Iwase R, Haruki K, Fujiwara Y, Furukawa K, Shiba H, Uwagawa T, Misawa T, Ohashi T, Yanaga K.
    J Surg Res; 2013 Sep; 184(1):605-12. PubMed ID: 23830367
    [Abstract] [Full Text] [Related]

  • 5. Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation.
    Uwagawa T, Chiao PJ, Gocho T, Hirohara S, Misawa T, Yanaga K.
    Anticancer Res; 2009 Aug; 29(8):3173-8. PubMed ID: 19661331
    [Abstract] [Full Text] [Related]

  • 6. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
    Meng H, Wang M, Liu H, Liu X, Situ A, Wu B, Ji Z, Chang CH, Nel AE.
    ACS Nano; 2015 Aug; 9(4):3540-57. PubMed ID: 25776964
    [Abstract] [Full Text] [Related]

  • 7. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma.
    Rogers JE, Mizrahi JD, Xiao L, Mohindroo C, Shroff RT, Wolff R, Varadhachary GR, Javle MM, Overman M, Fogelman DR, Raghav KPS, Pant S, McAllister F.
    Cancer Med; 2020 Aug; 9(15):5406-5415. PubMed ID: 32519420
    [Abstract] [Full Text] [Related]

  • 8. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
    Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, Philip PA, Abbruzzese J, Sarkar FH.
    Cancer Res; 2005 Oct 01; 65(19):9064-72. PubMed ID: 16204081
    [Abstract] [Full Text] [Related]

  • 9. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
    Melisi D, Xia Q, Paradiso G, Ling J, Moccia T, Carbone C, Budillon A, Abbruzzese JL, Chiao PJ.
    J Natl Cancer Inst; 2011 Aug 03; 103(15):1190-204. PubMed ID: 21743023
    [Abstract] [Full Text] [Related]

  • 10. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
    Zhuang Z, Li H, Lee H, Aguilar M, Gocho T, Ju H, Iida T, Ling J, Fu J, Wu M, Sun Y, Lu Y, Chiao PJ.
    Cancer Lett; 2017 Dec 28; 411():44-56. PubMed ID: 28951128
    [Abstract] [Full Text] [Related]

  • 11. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C, Leonard F, Lee Y, Zaid M, Elganainy D, Alexander JF, Kai M, Liu YT, Kang Y, Liu X, Koay EJ, Ferrari M, Godin B, Yokoi K.
    Cancer Lett; 2017 Sep 10; 403():296-304. PubMed ID: 28687352
    [Abstract] [Full Text] [Related]

  • 12. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
    Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ, Xu RH.
    J Pineal Res; 2016 Jan 10; 60(1):27-38. PubMed ID: 26445000
    [Abstract] [Full Text] [Related]

  • 13. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
    Awasthi N, Kronenberger D, Stefaniak A, Hassan MS, von Holzen U, Schwarz MA, Schwarz RE.
    Cancer Lett; 2019 Sep 10; 459():41-49. PubMed ID: 31153980
    [Abstract] [Full Text] [Related]

  • 14. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
    Rajeshkumar NV, Yabuuchi S, Pai SG, Tong Z, Hou S, Bateman S, Pierce DW, Heise C, Von Hoff DD, Maitra A, Hidalgo M.
    Br J Cancer; 2016 Aug 09; 115(4):442-53. PubMed ID: 27441498
    [Abstract] [Full Text] [Related]

  • 15. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
    Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB.
    Cancer Res; 2007 Apr 15; 67(8):3853-61. PubMed ID: 17440100
    [Abstract] [Full Text] [Related]

  • 16. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer.
    Harikumar KB, Kunnumakkara AB, Sethi G, Diagaradjane P, Anand P, Pandey MK, Gelovani J, Krishnan S, Guha S, Aggarwal BB.
    Int J Cancer; 2010 Jul 15; 127(2):257-68. PubMed ID: 19908231
    [Abstract] [Full Text] [Related]

  • 17. Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer.
    Wolfe AR, Robb R, Hegazi A, Abushahin L, Yang L, Shyu DL, Trevino JG, Cruz-Monserrate Z, Jacob JR, Palanichamy K, Chakravarti A, Williams TM.
    Clin Cancer Res; 2021 Jan 15; 27(2):554-565. PubMed ID: 33087331
    [Abstract] [Full Text] [Related]

  • 18. The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal adenocarcinoma.
    Kato A, Naiki-Ito A, Naitoh I, Hayashi K, Nakazawa T, Shimizu S, Nishi Y, Okumura F, Inoue T, Takada H, Kondo H, Yoshida M, Takahashi S, Joh T.
    Hum Pathol; 2018 Apr 15; 74():92-98. PubMed ID: 29339176
    [Abstract] [Full Text] [Related]

  • 19. Anti-tumor effect by inhibition of NF-kappaB activation using nafamostat mesilate for pancreatic cancer in a mouse model.
    Furukawa K, Iida T, Shiba H, Fujiwara Y, Uwagawa T, Shimada Y, Misawa T, Ohashi T, Yanaga K.
    Oncol Rep; 2010 Oct 15; 24(4):843-50. PubMed ID: 20811662
    [Abstract] [Full Text] [Related]

  • 20. Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.
    Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M, Al-Hallak MN, Tesfaye A, Kim S, Shidham V, M Mohammad R, Philip PA.
    Clin Cancer Res; 2020 Mar 15; 26(6):1338-1348. PubMed ID: 31831564
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.